This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Pruritus in palliative care

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Severe pruritus may be seen as a rare complication in some cancer patients (although mild pruritus may occur as a result of dry skin, candida infections or local inflammation).

In majority of patients severe pruritus can be attributed to cholestasis but other causes of itch in cancer patients include:

  • paraneoplastic itch – typically, suppression of the tumor growth will arrest pruritus and in some instances it may precedes diagnosis of cancer by months (or sometimes by years) e.g. – lymphomas
  • neuropathic itch – due to the damage caused by localized growth of the tumor (1)

Pruritus associated with obstructive jaundice often responds to simple measures such as emollients.

In cases of obstuctive jaundice, further measures include:

  • cholestyramine
  • rifampicin
  • naltrexone (1)
  • an anabolic steroid such as danazol (2)
  • antihistamines: chlorphenamine (piriton) 4mg 3 times/day may sedate - loratadine 10mg daily does not usually sedate

In paraneoplastic itch, patients may respond to paroxetine or sertraline therapy (1).

For neuropathic itch, Gabapentin may be useful (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.